Who
Jill Marie Broadfoot
Director
Company insider
Files Form 4 as: Director, Talphera; Chief Financial Officer, aTyr Pharma; Director, Cue Biopharma; Director, Otonomy; Sr Vice President, CFO, Sec, Vical.
In numbers
- Trades disclosed
- 93
- Buys
- 17
- Sells
- 6
- Bought
- $113K
- Sold
- $19K
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 6 Jan 2006
- Last trade
- 22 Jun 2026
- Last filed
- 24 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Jun 2026filed 24 Jun 2026 | TLPH TalpheraBiotechnology | SEC FORM 4 Code A | —5,100 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | TLPH Talpheraoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,700 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | TLPH Talpheraoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,700 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | TLPH TalpheraBiotechnology | SEC FORM 4 Code A | —5,100 at $0.00 | filing |
| 4 Feb 2026filed 4 Feb 2026 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Sold | $1,5211,558 at $0.976 | filing |
| 4 Feb 2026filed 4 Feb 2026 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Sold | $1,5271,558 at $0.98 | filing |
| 3 Feb 2026filed 4 Feb 2026 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Code M | —3,750 | filing |
| 3 Feb 2026filed 4 Feb 2026 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,750 at $0.00 | filing |
| 3 Feb 2026filed 4 Feb 2026 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,750 at $0.00 | filing |
| 3 Feb 2026filed 4 Feb 2026 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Code M | —3,750 | filing |
| 9 Jan 2026filed 9 Jan 2026 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —412,500 at $0.00 | filing |
| 9 Jan 2026filed 9 Jan 2026 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —412,500 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | CUE Cue Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,400 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | CUE Cue Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,400 at $0.00 | filing |
| 23 Oct 2025filed 24 Oct 2025 | TLPH Talpheraoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,600 at $0.00 | filing |
| 23 Oct 2025filed 24 Oct 2025 | TLPH TalpheraBiotechnology | SEC FORM 4 Code A | —4,267 at $0.00 | filing |
| 4 Jun 2025filed 6 Jun 2025 | CUE Cue Biopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —48,800 at $0.00 | filing |
| 4 Feb 2025filed 4 Feb 2025 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Sold | $4,7401,254 at $3.78 | filing |
| 3 Feb 2025filed 4 Feb 2025 | ATYR aTyr Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,750 at $0.00 | filing |
| 3 Feb 2025filed 4 Feb 2025 | ATYR aTyr PharmaBiotechnology | SEC FORM 4 Code M | —3,750 | filing |
News
No headline names them, or the companies they trade most, lately.